Immunai entered a multi-year research collaboration with Boehringer Ingelheim valued at up to $15 million through 2027, expanding how large pharma is using single-cell immune profiling paired with AI to identify T-cell targets. The project will analyze thousands of oncology and autoimmune patient samples to map T-cell dysfunction patterns tied to disease biology. In the initial phase, the companies will generate and apply multiomic immune profiles using single-cell RNA-seq, CITE-seq, ATAQ-seq, proteomics, and spatial transcriptomics. Immunai’s platform then integrates those profiles with AI models of the immune system to surface potential therapeutic targets for functional validation. Boehringer Ingelheim framed the work as a way to pursue novel modalities in areas where patients still face limited treatment options. Immunai said the oncology and autoimmune programs have historically been explored separately and that its approach is intended to uncover shared or distinct therapeutic leverage points using clinically grounded datasets. The collaboration follows Immunai’s expanded $37.5 million pact with AstraZeneca announced in May, reinforcing a steady cadence of Big Pharma partnerships tied to immune-cell discovery platforms.